Journal
NEW BIOTECHNOLOGY
Volume 28, Issue 5, Pages 511-517Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nbt.2011.03.020
Keywords
-
Funding
- NIH [AG032611, AG020197, DK075494]
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation/Association for Frontotemporal Dementia
- Irma T. Hirschl/Monique Weill-Caulier Trust
Ask authors/readers for more resources
Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease, Huntington's disease (HD) or amyotrophic lateral sclerosis (ALS) are all characterised histologically by the presence of deposits of misfolded proteins, tau and amyloid-beta, alpha-synuclein, huntingtin or superoxide dismutase, respectively. Currently, these illnesses do not have any disease modifying treatment options. A novel therapeutic strategy that is being pursued is immunomodulation, which is using the body's immune system to target the self-proteins that are deposited. Most of these promising approaches are still in preclinical development while some have progressed to Phase III clinical trials. As new insights are gained, it is hoped that these immunotherapies will be effective tools at slowing the progression of these debilitating diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available